ImmunoPrecise Antibodies (IPA) Competitors

ImmunoPrecise Antibodies (NASDAQ:IPA) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations.

Do insiders & institutionals have more ownership in IPA or EPRX?

6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts prefer IPA or EPRX?

ImmunoPrecise Antibodies presently has a consensus target price of $6.00, suggesting a potential upside of 936.27%. Given ImmunoPrecise Antibodies' higher possible upside, equities research analysts clearly believe ImmunoPrecise Antibodies is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoPrecise Antibodies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Eupraxia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Does the MarketBeat Community prefer IPA or EPRX?

ImmunoPrecise Antibodies received 9 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 90.91% of users gave ImmunoPrecise Antibodies an outperform vote.

Company	Underperform	Outperform
ImmunoPrecise Antibodies	Outperform Votes 10 90.91%	Underperform Votes 1 9.09%
Eupraxia Pharmaceuticals	Outperform Votes 1 100.00%	Underperform Votes No Votes

Which has higher earnings and valuation, IPA or EPRX?

ImmunoPrecise Antibodies has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoPrecise Antibodies	$24.52M	0.62	-$20.13M	-$0.41	-1.41
Eupraxia Pharmaceuticals	N/A	N/A	-$28.22M	-$1.00	-2.70

Is IPA or EPRX more profitable?

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -110.66%. ImmunoPrecise Antibodies' return on equity of -57.05% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunoPrecise Antibodies	-110.66%	-57.05%	-37.20%
Eupraxia Pharmaceuticals	N/A	-208.37%	-82.29%

Does the media prefer IPA or EPRX?

In the previous week, ImmunoPrecise Antibodies had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for ImmunoPrecise Antibodies and 4 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.55 beat ImmunoPrecise Antibodies' score of -0.52 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunoPrecise Antibodies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImmunoPrecise Antibodies beats Eupraxia Pharmaceuticals on 12 of the 17 factors compared between the two stocks.